A landmark study analyzing health data from more than 7 million individuals found that sildenafil (commonly known as Viagra) users had a 69% lower risk of developing Alzheimer's disease compared to non-users. The findings, led by experts at the Cleveland Clinic, appear in Nature Aging.
Sildenafil, primarily prescribed for erectile dysfunction and pulmonary hypertension, has previously shown promise in combating cancer and malaria. In this research, Dr. Feixiong Cheng and his team at the Cleveland Clinic used advanced computational methods to identify genetic factors influencing Alzheimer's, focusing on amyloid plaques and tau proteins—key hallmarks of the disease.
Prior in vitro studies on human brain cells also demonstrated that sildenafil promotes robust neuronal growth and reduces tau protein accumulation.
The analysis pinpointed 13 genetic modules linked to Alzheimer's phenotypes. Among over 1,600 FDA-approved drugs screened, sildenafil emerged as one of the top candidates for potential therapeutic benefits.
To validate these insights, the researchers examined insurance claims from over 7.2 million people. Sildenafil users showed a 69% reduced risk of Alzheimer's, with even stronger associations among those with coronary heart disease, hypertension, and type 2 diabetes.
While this establishes a strong correlation, it does not prove causation. Factors like physical activity or improved sleep among users could contribute. Nonetheless, the robust association positions sildenafil as a compelling candidate for future randomized clinical trials.
